

NYRx Formulary Update: Evotaz

February 3, 2026

What Pharmacy Providers and Prescribers Need to Know

NYRx, the Medicaid Pharmacy Program, claim history indicates that you have prescribed Evotaz for a New York Medicaid member. Bristol Myers Squibb announced a business decision to discontinue Evotaz (atazanavir/cobicistat) tablets on September 30, 2024. Discontinuation of manufacturing Evotaz globally is estimated to begin in April 2026. At this time, the drug supply may be limited.

What Prescribers Need to Do

Prescribers should switch their patients to products that remain available in the marketplace. For more information about coverage of Antiretroviral Agents for HIV Treatment, please see [Coverage of Antiretroviral Agents for HIV Treatment and HIV Pre-Exposure Prophylaxis](#).

Resources

- [Medicaid Pharmacy List of Reimbursable Drugs](#)
- [NYRx Education & Outreach Website](#)
- [NYRx Notice to Prescribers: Coverage of Anti-Retroviral \(ARV\) Agents for HIV Treatment](#)
- [NYRx Preferred Drug List](#)
- [NYRx Top Edit Resource](#)

Contact Information

The NYRx Education & Outreach Call Center is available by phone at 1-833-967-7310 or by email at NYRxEO@primetherapeutics.com from 8:00 AM to 5:00 PM ET, Monday through Friday, excluding holidays.

The NYRx Education & Outreach team hosts virtual office hours every week for stakeholders to ask questions related to NYRx and care coordination. Visit the [NYRx Education & Outreach website](#) for more information.